Research Article
Elevated Serum IL-17 Expression at Cessation Associated with Graves’ Disease Relapse
Table 1
Clinical features of GD patients with or without relapse.
| Parameters | Relapse | value | Yes () | No () |
| Age at diagnosis (year) | 45.3 ± 11.4 | 40.8 ± 10.3 | 0.029 | Gender (n, %) | | | 0.65 | Male | 9 (20.0%) | 17 (23.6%) | | Female | 36 (80.0%) | 55 (76.4%) | | Smokers (n, %) | 7(15.6%) | 10(13.9%) | 0.80 | Graves’ ophthalmopathy | 20(44.4%) | 18(25.0%) | 0.029 | Thyroglobulin (Tg, μg/L) | 51.7 ± 35.9 | 46.8 ± 33.2 | 0.45 | Thyroglobulin antibody positivity (%) | 12(26.7%) | 26(36.1%) | 0.29 | Anti-TPO (IU/L) | 121.5 ± 98.7 | 94.5 ± 69.1 | 0.085 | Duration of ATD therapy (months) | 20.2 ± 5.2 | 19.5 ± 6.8 | 0.56 | ATD drugs (n, %) | | | 0.65 | Methimazole | 36 (80.0%) | 60 (83.3%) | | Propylthiouracil | 9 (20.0%) | 12 (16.7%) | | Time to normalization of TSH (months) | 5.8 ± 2.1 | 4.6 ± 2.4 | 0.007 | Time to normalization of fT4 (months) | 2.2 ± 1.2 | 1.6 ± 0.9 | 0.003 | Thyroid function tests at diagnosis | | | | fT4 (pmol/L) | 31.6 ± 15.1 | 30.8 ± 14.7 | 0.72 | TT3 (nmol/L) | 5.2 ± 1.3 | 4.8 ± 1.6 | 0.16 | TSH (mIU/L) | 0.06 ± 0.05 | 0.06 ± 0.04 | 1.00 | TRAb (IU/L) | 7.7 ± 5.8 | 6.7 ± 4.8 | 0.31 | TSAb (%) | 422.1 ± 172.4 | 482.3 ± 201.5 | 0.10 | Thyroid function tests at cessation | | | | fT4 (pmol/L) | 17.5 ± 2.9 | 16.8 ± 3.6 | 0.27 | TT3 (nmol/L) | 2.2 ± 0.5 | 2.3 ± 0.6 | 0.35 | TSH (mIU/L) | 2.5 ± 1.4 | 3.2 ± 1.5 | 0.013 | TRAb (IU/L) | 1.2 ± 0.8 | 0.8 ± 0.5 | 0.001 | TSAb (%) | 214.4 ± 114.8 | 218.5 ± 109.7 | 0.85 |
|
|
GD: Graves’ disease; ATD: antithyroid drug; Anti-TPO: antithyroid peroxidase antibody; fT4: free thyroxine; TT3: total triiodothyronine; TSH: thyrotropin-stimulating hormone; TRAb: thyrotropin receptor antibody; TSAb: thyroid stimulatory antibody. values were calculated by Student’s t-test, Mann–Whitney U test, and chi-squared test. . |